These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32541966)

  • 1. Single-molecule analysis reveals agonist-specific dimer formation of µ-opioid receptors.
    Möller J; Isbilir A; Sungkaworn T; Osberg B; Karathanasis C; Sunkara V; Grushevskyi EO; Bock A; Annibale P; Heilemann M; Schütte C; Lohse MJ
    Nat Chem Biol; 2020 Sep; 16(9):946-954. PubMed ID: 32541966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
    Liu JG; Prather PL
    Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of μ receptors by SR-17018 through a distinctive mechanism.
    Singleton S; Dieterle C; Walker DJ; Runeberg T; Oswald AS; Rosenqvist G; Robertson L; McCarthy T; Sarkar S; Baptista-Hon D; Hales TG
    Neuropharmacology; 2024 Nov; 258():110093. PubMed ID: 39067665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonist stimulation at human μ opioid receptors in a [(35)S]GTPγS incorporation assay: observation of "bell-shaped" concentration-response relationships under conditions of strong receptor G protein coupling.
    Heusler P; Tardif S; Cussac D
    J Recept Signal Transduct Res; 2016; 36(2):158-66. PubMed ID: 26466637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
    Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
    Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors.
    Xu H; Wang X; Partilla JS; Bishop-Mathis K; Benaderet TS; Dersch CM; Simpson DS; Prisinzano TE; Rothman RB
    Brain Res Bull; 2008 Sep; 77(1):49-54. PubMed ID: 18639745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
    Wang D; Sun X; Sadee W
    J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of agonist-dependent receptor internalization in the regulation of mu opioid receptors.
    Sternini C; Brecha NC; Minnis J; D'Agostino G; Balestra B; Fiori E; Tonini M
    Neuroscience; 2000; 98(2):233-41. PubMed ID: 10854754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Internalization and recycling of human mu opioid receptors expressed in Sf9 insect cells.
    Chen LE; Gao C; Chen J; Xu XJ; Zhou DH; Chi ZQ
    Life Sci; 2003 May; 73(1):115-28. PubMed ID: 12726892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
    Liu-Chen LY; Yang HH; Li S; Adams JU
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence.
    Xu H; Partilla JS; Wang X; Rutherford JM; Tidgewell K; Prisinzano TE; Bohn LM; Rothman RB
    Synapse; 2007 Mar; 61(3):166-75. PubMed ID: 17152090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
    Yoburn BC; Purohit V; Patel K; Zhang Q
    Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.
    Divin MF; Bradbury FA; Carroll FI; Traynor JR
    Br J Pharmacol; 2009 Apr; 156(7):1044-53. PubMed ID: 19220294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a κ Partial Agonist and μ Partial Agonist.
    Wang YH; Chai JR; Xu XJ; Ye RF; Zan GY; Liu GY; Long JD; Ma Y; Huang X; Xiao ZC; Dong H; Wang YJ
    Sci Rep; 2018 Sep; 8(1):14087. PubMed ID: 30237513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent antagonism of spinal opioid receptor agonists by naloxone and naltrindole: additional evidence for delta-opioid receptor subtypes in the rat.
    Tiseo PJ; Yaksh TL
    Eur J Pharmacol; 1993 May; 236(1):89-96. PubMed ID: 8391455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.
    Beattie DT; Cheruvu M; Mai N; O'Keefe M; Johnson-Rabidoux S; Peterson C; Kaufman E; Vickery R
    Naunyn Schmiedebergs Arch Pharmacol; 2007 May; 375(3):205-20. PubMed ID: 17340127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors.
    Borgland SL; Connor M; Osborne PB; Furness JB; Christie MJ
    J Biol Chem; 2003 May; 278(21):18776-84. PubMed ID: 12642578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
    Wang D; Raehal KM; Bilsky EJ; Sadée W
    J Neurochem; 2001 Jun; 77(6):1590-600. PubMed ID: 11413242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged morphine treatment alters δ opioid receptor post-internalization trafficking.
    Ong EW; Xue L; Olmstead MC; Cahill CM
    Br J Pharmacol; 2015 Jan; 172(2):615-29. PubMed ID: 24819092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.
    Spivak CE; Beglan CL; Seidleck BK; Hirshbein LD; Blaschak CJ; Uhl GR; Surratt CK
    Mol Pharmacol; 1997 Dec; 52(6):983-92. PubMed ID: 9415708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.